The U.S. Food and Drug Administration rejected a proposed pill that would combine the drugs Claritin and Singular, Schering-Plough said.
The drug, a combination of loratadine and montelukast developed in a joint venture between Schering-Plough and Merck Pharmaceuticals, was targeted for patients with allergic rhinitis symptoms and nasal congestion.
The active ingredients of Claritin is loratadine and the active ingredient of Singulair is montelukast sodium. Both drugs are indicated for the relief of symptoms of seasonal allergic rhinitis and perennial allergic rhinitis, the two drug companies said in a statement.
The companies did not explain the FDA's reason for rejecting the drug combo.
Copyright 2008 by United Press International
Related stories:
Government probes chelation-heart disease study
(AP) -- The largest alternative medicine study the government has ever launched has stopped enrolling people while officials investigate whether participants were fully informed of the risks and are being adequately protected, The Associated Press has learned.
FDA cracks down on eye wash and skin cream
(AP) -- Federal officials on Tuesday launched a crackdown against several companies that market an eye wash and a widely used skin cream without government approval, saying these prescription medications could pose risks.
Rodent studies suggest mother's diet can affect genes and offspring's risk of allergic asthma
A pregnant mouse's diet can induce epigenetic changes that increase the risk her offspring will develop allergic asthma, according to researchers at National Jewish Health and Duke University Medical Center. Pregnant mice that consumed diets high in supplements containing methyl-donors, such as folic acid, had offspring with more severe allergic airway disease than offspring from mice that consumed diets low in methyl-containing foods. The results of the study are being published Sept. 18, 2008, in the online version of the
Journal of Clinical Investigation and will appear in the October print issue.
Pill that boosts productivity gaining favor, raising concerns among medical ethicists
In a place like Silicon Valley, where career prospects often hinge on a person's intelligence and ability to work hellishly long hours, "brain doping" probably was inevitable.
Report suggests allopurinol may lower blood pressure in teens with hypertension
The drug allopurinol, which lowers uric acid levels, appears to reduce blood pressure in adolescents with newly diagnosed hypertension, according to a preliminary report in the August 27 issue of
JAMA.
Chemists move closer toward developing safer, fully-synthetic form of heparin
Chemists are reporting a major advance toward developing a safer, fully-synthetic version of heparin, the widely used blood thinner now produced from pig intestines. The U. S. Food and Drug Administration last spring linked contaminated batches of the animal-based product, imported from China, to more than 80 deaths and hundreds of allergic reactions among patients exposed to the drug for kidney dialysis and other conditions.
Novel study finds proton channels inhibit the release of histamine during allergic reactions
Inhibiting the proton currents in basophils, a rare type of white blood cell, can stop the release of histamine and could provide a new target for allergy and asthma drugs according to a new study by researchers at Rush University Medical Center in Chicago and the Johns Hopkins Asthma and Allergy Center in Baltimore. The research is published in the August 5th issue the
Proceedings of the National Academy of Sciences.
'Stuffy nose' mouse: A promise to help treat 31 million with sinusitis
Mice with inflamed nasal tissue being tested at a Johns Hopkins laboratory may be unable to tell if something smells bad or good, but their sensory deficit is nothing to turn up a nose at.